

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5148193

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	DOMAIN THERAPEUTICS S.A.	06/20/2018
RECEIVING PARTY DATA		
Name:	MAVALON THERAPEUTICS LIMITED	
Street Address:	BRIDGE HOUSE, 25 FIDDLE BRIDGE LANE	
City:	HATFIELD	
State/Country:	UNITED KINGDOM	
Postal Code:	AL 10 OSP	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	15775725
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	dmatocha@phiplaw.com	
Correspondent Name:	PARKER HIGHLANDER	
Address Line 1:	1120 S. CAPITAL OF TEXAS HIGHWAY	
Address Line 2:	BUILDING ONE, SUITE 200	
Address Line 4:	AUSTIN, TEXAS 78746	
ATTORNEY DOCKET NUMBER:	VOSS.P0087US	
NAME OF SUBMITTER:	DEE MATOCHA	
SIGNATURE:	/Dee Matocha/	
DATE SIGNED:	09/19/2018	
Total Attachments: 4		
source=VOSS_P0087US_ExecutedAssignment_DomainToMavalon#page1.tif		
source=VOSS_P0087US_ExecutedAssignment_DomainToMavalon#page2.tif		
source=VOSS_P0087US_ExecutedAssignment_DomainToMavalon#page3.tif		
source=VOSS_P0087US_ExecutedAssignment_DomainToMavalon#page4.tif		

ASSIGNMENT

This Patent Assignment ("**Assignment**") is made and entered into by and between **Domain Therapeutics S.A.**, a company organized and existing under the laws France, having a place of business at Bioparc, 850 Boulevard Sébastien Brant, Illkirch-Strasbourg, 67400 France (the "**Assignor**") and **Mavalon Therapeutics Limited**, a company organized and existing under the laws of United Kingdom, having a place of business at Bridge House, 25 Fiddle Bridge Lane, Hatfield, Hertfordshire, AL10 0SP, United Kingdom (the "**Assignee**").

WHEREAS, Assignor has agreed to assign and transfer to Assignee, and Assignee has agreed to acquire and accept from Assignor, Assignor's rights in the following patent applications (the "**Assigned Patents**"):

U.S. Application No. 15/775,725, entitled "SUBSTITUTED TRICYCLIC 1,4-BENZODIAZEPINONE DERIVATIVES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS," filed May 11, 2018;

International Application No. PCT/GB2016/053550, filed November 11, 2016; and

European Application No. 15194611.8, filed November 13, 2015.

NOW, THEREFORE, in consideration of the premises, mutual covenants and provisions herein contained, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound hereby, the parties hereto agree to execute this Assignment, as follows:

1.0 Assignment. Assignor has assigned and/or by these presents does hereby assign, transfer and convey unto Assignee, Assignor's whole and entire right, title and interest for the United States and for all other countries throughout the world (i) in and to the inventions claimed or disclosed in the Assigned Patents, including all patents granting from said applications on said Assigned Patents or any continuation, continuation-in-part, division, renewal, substitute, reexamination or reissue thereof, including any patents in the United States and in all other countries throughout the world obtained based upon a claim of priority to any patent or patent application on said Assigned Patents as provided for by United States law, the Patent Cooperation Treaty, the European Patent Convention, the Paris Convention, or other applicable law, as well as the right to claim priority to any patent or patent application on said Assigned Patents as provided for by United States law, the Patent Cooperation Treaty, the European Patent Convention, the Paris Convention, or other applicable law, and (ii) in and to all rights to sue for and collect damages resulting from past, present and future infringement of said patents and patent applications in (i).

2.0 Enjoyment. The patents and patent applications subject to Paragraph 1 shall be held and enjoyed by Assignee, for Assignee's use and benefit, and for Assignee's legal representatives and assigns, to the full end of the term or terms for which same may be granted, as fully and entirely as the same would have been held by Assignor had this assignment and transfer not been made.

3.0 Authorize and Request. Assignor authorizes and requests the issuing authority to issue any and all United States and foreign patents granted on such patents and patent applications in 1.0(i) to the Assignee.

{00554202}

4.0 Warrant And Covenant. Assignor warrants and covenants that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been or will be made to others by the Assignor, and that the full right to convey the same as herein expressed is possessed by the Assignor.

5.0 Assistance. The parties to this Assignment shall use commercially reasonable efforts to take, or cause to be taken, all actions, and to do, or cause to be done, all things, necessary or advisable to consummate the transactions contemplated by this Assignment. Without limiting the foregoing, each of Assignor and Assignee shall cooperate with the other without any further consideration to execute and deliver, or use commercially reasonable efforts to cause to be executed and delivered, all documents as may reasonably be necessary to secure the vesting in Assignee of all rights assigned to Assignee by this Assignment, including without limitation any documents required to record this Assignment with local patent offices, and all rightful oaths, declarations, and other papers.

6.0 Binding. The Assignment is binding on the heirs, assigns, representatives and successors of the Assignor and extends to the successors, assigns and nominees of the Assignee.

7.0 Effectiveness. The assignment of said inventions is effective as of the date of execution of the Assignor indicated below.

(Signature page follows)

IN WITNESS WHEREOF, Assignor has executed this Patent Assignment, or has caused this Patent Assignment to be executed on its behalf by a representative duly authorized, all as of the date set forth below.

Domain Therapeutics S.A.

By: 

Name: NEVILLE, PASCAL

Title: CEO

Date: June 20, 2018

BEFORE ME, the undersigned authority, on this 20th day of June, 2018 personally appeared Pascal NEVILLE known to me to be the person whose name is subscribed to the foregoing instrument and acknowledged to me that he/she executed the same of his/her own free will for the purposes and consideration therein expressed.

Sophie BLOCH

Witness



IN WITNESS WHEREOF, Assignee has executed this Patent Assignment, or has caused this Patent Assignment to be executed on its behalf by a representative duly authorized, all as of the date set forth below.

Mavalon Therapeutics Limited

By: 

Name: H. OLIVIER

Title: Director

Date: 29/6/18

BEFORE ME, the undersigned authority, on this 29th day of June, 2018 personally appeared Dominic OLIVIER, known to me to be the person whose name is subscribed to the foregoing instrument and acknowledged to me that he/she executed the same of his/her own free will for the purposes and consideration therein expressed.

Dominic BENICOURT

Witness

